Effectiveness of bivalent COVID-19 boosters against COVID-19 mortality in people aged 65 years and older, Australia, November 2022 to May 2023

We followed 4,081,257 Australian adults aged ≥ 65 years between November 2022 and May 2023 for COVID-19-specific mortality, when recombinant SARS-CoV-2 Omicron lineages (predominantly XB and XBB) as well as BA.2.75 were circulating. Compared with a COVID-19 booster targeting ancestral SARS-CoV-2 giv...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Bette, Stepien, Sandrine, Sharma, Ketaki, Macartney, Kristine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2023
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668254/
https://www.ncbi.nlm.nih.gov/pubmed/37997663
http://dx.doi.org/10.2807/1560-7917.ES.2023.28.47.2300603
_version_ 1785149095230308352
author Liu, Bette
Stepien, Sandrine
Sharma, Ketaki
Macartney, Kristine
author_facet Liu, Bette
Stepien, Sandrine
Sharma, Ketaki
Macartney, Kristine
author_sort Liu, Bette
collection PubMed
description We followed 4,081,257 Australian adults aged ≥ 65 years between November 2022 and May 2023 for COVID-19-specific mortality, when recombinant SARS-CoV-2 Omicron lineages (predominantly XB and XBB) as well as BA.2.75 were circulating. Compared with a COVID-19 booster targeting ancestral SARS-CoV-2 given > 180 days earlier, the relative vaccine effectiveness against COVID-19 death of a bivalent (ancestral/BA.1 or ancestral/BA.4-5) booster given 8 to 90 days earlier was 66.0% (95%CI: 57.6 to 72.2%) and that of a monovalent ancestral booster given 8 to 90 days earlier was 44.7% (95%CI: 23.9 to 59.7%).
format Online
Article
Text
id pubmed-10668254
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-106682542023-11-23 Effectiveness of bivalent COVID-19 boosters against COVID-19 mortality in people aged 65 years and older, Australia, November 2022 to May 2023 Liu, Bette Stepien, Sandrine Sharma, Ketaki Macartney, Kristine Euro Surveill Rapid Communication We followed 4,081,257 Australian adults aged ≥ 65 years between November 2022 and May 2023 for COVID-19-specific mortality, when recombinant SARS-CoV-2 Omicron lineages (predominantly XB and XBB) as well as BA.2.75 were circulating. Compared with a COVID-19 booster targeting ancestral SARS-CoV-2 given > 180 days earlier, the relative vaccine effectiveness against COVID-19 death of a bivalent (ancestral/BA.1 or ancestral/BA.4-5) booster given 8 to 90 days earlier was 66.0% (95%CI: 57.6 to 72.2%) and that of a monovalent ancestral booster given 8 to 90 days earlier was 44.7% (95%CI: 23.9 to 59.7%). European Centre for Disease Prevention and Control (ECDC) 2023-11-23 /pmc/articles/PMC10668254/ /pubmed/37997663 http://dx.doi.org/10.2807/1560-7917.ES.2023.28.47.2300603 Text en This article is copyright of the authors or their affiliated institutions, 2023. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Rapid Communication
Liu, Bette
Stepien, Sandrine
Sharma, Ketaki
Macartney, Kristine
Effectiveness of bivalent COVID-19 boosters against COVID-19 mortality in people aged 65 years and older, Australia, November 2022 to May 2023
title Effectiveness of bivalent COVID-19 boosters against COVID-19 mortality in people aged 65 years and older, Australia, November 2022 to May 2023
title_full Effectiveness of bivalent COVID-19 boosters against COVID-19 mortality in people aged 65 years and older, Australia, November 2022 to May 2023
title_fullStr Effectiveness of bivalent COVID-19 boosters against COVID-19 mortality in people aged 65 years and older, Australia, November 2022 to May 2023
title_full_unstemmed Effectiveness of bivalent COVID-19 boosters against COVID-19 mortality in people aged 65 years and older, Australia, November 2022 to May 2023
title_short Effectiveness of bivalent COVID-19 boosters against COVID-19 mortality in people aged 65 years and older, Australia, November 2022 to May 2023
title_sort effectiveness of bivalent covid-19 boosters against covid-19 mortality in people aged 65 years and older, australia, november 2022 to may 2023
topic Rapid Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668254/
https://www.ncbi.nlm.nih.gov/pubmed/37997663
http://dx.doi.org/10.2807/1560-7917.ES.2023.28.47.2300603
work_keys_str_mv AT liubette effectivenessofbivalentcovid19boostersagainstcovid19mortalityinpeopleaged65yearsandolderaustralianovember2022tomay2023
AT stepiensandrine effectivenessofbivalentcovid19boostersagainstcovid19mortalityinpeopleaged65yearsandolderaustralianovember2022tomay2023
AT sharmaketaki effectivenessofbivalentcovid19boostersagainstcovid19mortalityinpeopleaged65yearsandolderaustralianovember2022tomay2023
AT macartneykristine effectivenessofbivalentcovid19boostersagainstcovid19mortalityinpeopleaged65yearsandolderaustralianovember2022tomay2023

Ejemplares similares